Literature DB >> 21993017

Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-κB and is associated with poor patient outcome.

Oh-Hyung Kwon1, Sung-Joon Park, Tae-Wook Kang, Mirang Kim, Jeong-Hwan Kim, Seung-Moo Noh, Kyu-Sang Song, Hyang-Sook Yoo, Yuli Wang, David Pocalyko, Sang-Gi Paik, Yeul-Hong Kim, Seon-Young Kim, Yong Sung Kim.   

Abstract

The fibroblast growth factor-inducible 14 (Fn14) gene encodes a type I transmembrane protein that belongs to the tumor necrosis factor receptor superfamily and regulates multiple cellular processes in diverse physiological and pathological conditions, including cancer. Here, we describe an important role for Fn14 in regulating the growth of gastric cancer cells. Previous gene expression data analysis demonstrated that Fn14 was up-regulated in various tumor tissues, including gastric cancer. Using qRT-PCR, we showed that Fn14 was overexpressed in gastric tumor tissues compared to normal tissues. Furthermore, Fn14 expression levels were inversely correlated with gastric cancer patient survival. Using ectopic overexpression and shRNA-mediated knockdown of Fn14, we demonstrated that the expression level of Fn14 affected cell growth in gastric cancer. The effect of Fn14 on cell growth was mediated by the NF-κB activity and eventually by the transcriptional regulation of the anti-apoptotic Bcl-2 family gene (Bcl-xL). These results suggest that Fn14 may play an important role in gastric tumor growth by regulating NF-κB-mediated anti-apoptosis and that Fn14 may be a useful prognostic marker for gastric cancer.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993017     DOI: 10.1016/j.canlet.2011.09.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

Review 1.  The TWEAK-Fn14 system as a potential drug target.

Authors:  Harald Wajant
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

2.  Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer.

Authors:  Francesc Xavier Avilés-Jurado; Ximena Terra; David Gómez; Joan Carles Flores; Antoni Raventós; Elsa Maymó-Masip; Xavier León; Vicente Serrano-Gonzalvo; Joan Vendrell; Enric Figuerola; Matilde R Chacón
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-26       Impact factor: 2.503

3.  Fn14 receptor promotes invasive potential and metastatic capacity of non-small lung adenocarcinoma cells through the up-regulation of integrin α6.

Authors:  J Jandova; C J Mason; S C Pawar; G S Watts
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

4.  Regulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradation.

Authors:  Sujatha Gurunathan; Jeffrey A Winkles; Sankar Ghosh; Matthew S Hayden
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

5.  Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.

Authors:  Hong Zhou; Khalid A Mohamedali; Ana Maria Gonzalez-Angulo; Yu Cao; Mary Migliorini; Lawrence H Cheung; Janine LoBello; Xiudong Lei; Yuan Qi; Walter N Hittelman; Jeffrey A Winkles; Nhan L Tran; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

6.  The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.

Authors:  Kaushal Asrani; Ruth A Keri; Rebeca Galisteo; Sharron A N Brown; Sarah J Morgan; Arundhati Ghosh; Nhan L Tran; Jeffrey A Winkles
Journal:  Mol Cancer Res       Date:  2013-02-01       Impact factor: 5.852

7.  Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.

Authors:  Hong Zhou; Walter N Hittelman; Hideo Yagita; Lawrence H Cheung; Stuart S Martin; Jeffrey A Winkles; Michael G Rosenblum
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

8.  Disruption of the TWEAK/Fn14 pathway prevents 5-fluorouracil-induced diarrhea in mice.

Authors:  Takuhito Sezaki; Yuki Hirata; Teruki Hagiwara; Yuki I Kawamura; Tadashi Okamura; Rieko Takanashi; Kenta Nakano; Miwa Tamura-Nakano; Linda C Burkly; Taeko Dohi
Journal:  World J Gastroenterol       Date:  2017-04-07       Impact factor: 5.742

9.  The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion.

Authors:  Emily Cheng; Timothy G Whitsett; Nhan L Tran; Jeffrey A Winkles
Journal:  Mol Cancer Res       Date:  2014-11-12       Impact factor: 5.852

10.  The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.

Authors:  Hong Zhou; Suhendan Ekmekcioglu; John W Marks; Khalid A Mohamedali; Kaushal Asrani; Keeley K Phillips; Sharron A N Brown; Emily Cheng; Michele B Weiss; Walter N Hittelman; Nhan L Tran; Hideo Yagita; Jeffrey A Winkles; Michael G Rosenblum
Journal:  J Invest Dermatol       Date:  2012-11-29       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.